查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球病毒性呼吸道感染治疗市场—产业趋势与预测（截至 2031 年）
市场调查报告书
商品编码
1398957

全球病毒性呼吸道感染治疗市场—产业趋势与预测（截至 2031 年）

Global Viral Respiratory Infections Treatment Market - Industry Trends and Forecast to 2031
出版日期: | 出版商: Data Bridge Market Research | 英文 570 Pages | 商品交期: 请询问到货日

价格

2023年，全球病毒性呼吸道感染治疗市场规模将达到573.6534亿美元，到2031年将达到1082.0705亿美元，预计在2024-2031年预测期内复合年增长率为8.5%。

本报告研究和分析了全球病毒性呼吸道感染治疗市场，提供有关行业趋势和预测、驱动因素和限制因素、公司趋势等资讯。

目录

第 1 章 简介

第二章 市场区隔

第三章执行摘要

第 4 章重要注意事项

  • PESTEL 分析
  • 波特五力分析
  • 品牌分析

第五章全球病毒性呼吸道感染治疗市场：监管

  • 美国法规
  • 欧洲法规
  • 印度法规
  • 日本法规

第六章市场概况

  • 促进者
    • 病毒性呼吸道感染爆发
    • 政府措施和疫苗接种计划
    • 医学研究和技术的进步
    • 提高对 RSV 的认识
  • 抑制因素
    • 严格的监管审批流程
    • 对熟练医护人员的依赖
  • 机会
    • 增加联合研究活动和伙伴关係
    • 抗病毒药物研发进展
    • 越来越重视个人化治疗选择
  • 任务
    • 抗病毒药物的过度使用和滥用
    • 诊断准确性和可访问性

第七章全球病毒呼吸道感染治疗市场：依治疗类型

  • 概述
  • 非类固醇类抗发炎药 (NSAID)
    • 阿斯匹灵（乙酰水杨酸）
    • 布洛芬
    • □普生
    • 双氯芬酸
    • 塞来昔布
    • 其他
  • 抗病毒药
    • 按类型
    • 依药物类型
  • 疫苗接种
    • COVID-19
    • 流感
    • 呼吸道合胞病毒
    • 其他
  • 单克隆抗体
    • 按类型
    • 依药物类型
  • 其他

第八章全球病毒性呼吸道感染治疗市场：依类型

  • 概述
  • 处方基础
  • 场外交易

第九章全球病毒呼吸道感染治疗市场：依给药途径

  • 概述
  • 鼻腔
  • 口服
    • 药片
    • 液体
    • 其他
  • 注射
    • 静脉
    • 其他

第十章全球病毒性呼吸道感染治疗市场：依疾病分类

  • 概述
  • COVID-19
  • 鼻病毒（感冒）
  • 呼吸道合胞病毒
  • 流感
  • 副流感
    • HPIV-1
    • HPIV-2
    • HPIV-3
    • HPIV-4
  • 腺病毒
  • 肠病毒
    • 柯萨奇病毒 (CV)
    • 小儿麻痹病毒（PV）
    • 其他
  • 其他

第十一章全球病毒性呼吸道感染治疗市场：依传染病类型

  • 概述
  • 下呼吸道感染
  • 上呼吸道感染

第十二章全球病毒性呼吸道感染治疗市场：依人口分类

  • 概述
  • 老年人
  • 孩子
  • 成人

第十三章全球病毒性呼吸道感染治疗市场：性别

  • 概述
  • 男性
  • 女士

第14章全球病毒呼吸道感染治疗市场：依最终用户分类

  • 概述
  • 医院
    • 私立
    • 公共
  • 门诊手术中心
  • 诊所
  • 居家护理环境
  • 研究机构、学术中心

第十五章全球病毒性呼吸道感染治疗市场：按分销管道

  • 概述
  • 直接报价
  • 零售
    • 医院药房
    • 零售药店
    • 网上药店
  • 其他

第十六章全球病毒性呼吸道感染治疗市场：按地区

  • 概述
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 意大利
    • 俄罗斯
    • 西班牙
    • 土耳其
    • 荷兰
    • 瑞士
    • 比利时
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 新加坡
    • 泰国
    • 马来西亚
    • 印度尼西亚
    • 菲律宾
    • 亚太其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 中东/非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 埃及
    • 以色列
    • 其他中东/非洲

第十七章全球病毒性呼吸道感染治疗市场：公司状况

  • 公司股票分析：全球
  • 公司股票分析：北美
  • 公司股票分析：欧洲
  • 公司股票分析：亚太地区

第18章SWOT分析

第十九章公司简介

  • PFIZER INC.
  • GSK PLC
  • GILEAD SCIENCES, INC
  • F. HOFFMANN-LA ROCHE LTD
  • JOHNSON & JOHNSON SERVICES, INC.
  • ASTRAZENECA
  • BHARAT BIOTECH
  • BIOLOGICAL E LIMITED
  • CELLTRION HEALTHCARE CO., LTD.
  • INFLARX N.V.
  • LILLY
  • REGENERON PHARMACEUTICALS INC.
  • SERUM INSTITUTE OF INDIA PVT. LTD
  • SINOVAC
  • SWEDISH ORPHAN BIOVITRUM AB (PUBL)

第20章调查

第21章 相关报导

The global viral respiratory infections treatment market is expected to reach USD 108,207.05 million by 2031 from USD 57,365.34 million in 2023, growing at a CAGR of 8.5% in the forecast period of 2024 to 2031.

Market Segmentation

Global Viral Respiratory Infections Treatment Market, By Treatment Type (Antiviral Medications, Vaccines, Monoclonal Antibodies, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others), Type (OTC and Prescription Based), Route of Administration (Oral, Nasal, and Injectable), Disease Type (COVID, Influenza (Flu), Respiratory Syncytial Virus (RSV), Parainfluenza, Adenoviruses, Rhinovirus (Common Cold), Enterovirus, Anti-inflammatory, and Others), Infection Type (Upper Respiratory Infections and Lower Respiratory Infections), Population Type (Pediatric, Adults, and Geriatric), Gender (Male and Female), End User (Hospitals, Home Care Settings, Clinics, Research Institutes and Academic Centers, and Ambulatory Surgical Centers), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Denmark, Sweden, Poland, Norway, Finland, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, New Zealand, Taiwan, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Bahrain, Oman, Kuwait, Qatar, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Overview of Global Viral Respiratory Infections Treatment Market Dynamics

  • Driver
  • Increasing prevalence of viral respiratory infections
  • Restraint
  • Stringent regulatory approval processes
  • Opportunity
  • Rising collaborative research activities and partnerships

Market Players

Some of the major market players operating in the global viral respiratory infections treatment market are:

  • Pfizer Inc.
  • GSK plc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • SINOVAC
  • Lilly
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc.
  • Bharat Biotech.
  • Swedish Orphan Biovitrum AB (publ)
  • Serum Institute of India Pvt. Ltd.
  • Biological E Limited
  • Celltrion Healthcare Co.,Ltd.
  • InflaRx N.V.

TABLE OF CONTENTS

1 INTRODUCTION 62

  • 1.1 OBJECTIVES OF THE STUDY 62
  • 1.2 MARKET DEFINITION 62
  • 1.3 OVERVIEW OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET 62
  • 1.4 CURRENCY AND PRICING 64
  • 1.5 LIMITATIONS 64
  • 1.6 MARKETS COVERED 64

2 MARKET SEGMENTATION 68

  • 2.1 MARKETS COVERED 68
  • 2.2 GEOGRAPHICAL SCOPE 69
  • 2.3 YEARS CONSIDERED FOR THE STUDY 70
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 71
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
  • 2.6 DBMR MARKET POSITION GRID 75
  • 2.7 MULTIVARIATE MODELLING 76
  • 2.8 TYPE LIFELINE CURVE 76
  • 2.9 MARKET END USER COVERAGE GRID 77
  • 2.10 SECONDARY SOURCES 78
  • 2.11 ASSUMPTIONS 78

3 EXECUTIVE SUMMARY 79

4 PREMIUM INSIGHTS 83

  • 4.1 PESTEL ANALYSIS 85
  • 4.2 PORTER'S FIVE FORCES 86
  • 4.3 BRAND ANALYSIS 87

5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: REGULATIONS 88

  • 5.1 REGULATIONS IN THE U.S.: 88
  • 5.2 REGULATIONS IN EUROPE 89
  • 5.3 REGULATIONS IN INDIA: 89
  • 5.4 REGULATIONS IN JAPAN 90

6 MARKET OVERVIEW 91

  • 6.1 DRIVERS 93
    • 6.1.1 INCREASING PREVALENCE OF VIRAL RESPIRATORY INFECTIONS 93
    • 6.1.2 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS 93
    • 6.1.3 ADVANCEMENTS IN MEDICAL RESEARCH AND TECHNOLOGY 95
    • 6.1.4 GROWING AWARENESS ASSOCIATED WITH RSVS 96
  • 6.2 RESTRAINTS 96
    • 6.2.1 STRINGENT REGULATORY APPROVAL PROCESSES 96
    • 6.2.2 DEPENDENCY ON SKILLED MEDICAL PERSONNEL 97
  • 6.3 OPPORTUNITIES 98
    • 6.3.1 RISING COLLABORATIVE RESEARCH ACTIVITIES AND PARTNERSHIPS 98
    • 6.3.2 ADVANCEMENTS IN ANTIVIRAL DRUG DEVELOPMENT 98
    • 6.3.3 GROWING FOCUS ON PERSONALIZED TREATMENT OPTIONS 99
  • 6.4 CHALLENGES 100
    • 6.4.1 OVERUSE AND MISUSE OF ANTIVIRALS 100
    • 6.4.2 DIAGNOSTIC ACCURACY AND ACCESSIBILITY 100

7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE 102

  • 7.1 OVERVIEW 103
  • 7.2 NON-STEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS) 106
    • 7.2.1 ASPIRIN (ACETYLSALICYLATE) 106
    • 7.2.2 IBUPROFEN 106
    • 7.2.3 NAPROXEN 107
    • 7.2.4 DICLOFENAC 107
    • 7.2.5 CELECOXIB 107
    • 7.2.6 OTHERS 107
  • 7.3 ANTIVIRAL MEDICATIONS 107
    • 7.3.1 BY TYPE 108
      • 7.3.1.1 OSELTAMIVIR 108
      • 7.3.1.2 ZANAMIVIR 108
      • 7.3.1.3 PERAMIVIR 108
      • 7.3.1.4 BALOXAVIR MARBOXIL 108
      • 7.3.1.5 REMEDESVIR 109
      • 7.3.1.6 NIRMATRELVIR/ RITONAVIR 109
      • 7.3.1.7 MOLNUPIRAVIR 109
      • 7.3.1.8 FAVILAVIR 109
      • 7.3.1.9 OTHERS 109
    • 7.3.2 BY DRUG TYPE 109
      • 7.3.2.1 BRANDED 109
      • 7.3.2.2 GENERIC 109 
  • 7.4 VACCINE 110
    • 7.4.1 COVID 111
      • 7.4.1.1 BY TYPE 111
        • 7.4.1.1.1 WHOLE VIRUS VACCINE 111
        • 7.4.1.1.1.1 INACTIVATED VACCINE 111
        • 7.4.1.1.1.2 LIVE ATTENUATED VACCINE 111
        • 7.4.1.1.2 COMPONENT VIRAL VACCINE 112
        • 7.4.1.1.2.1 MESSENGER RNA (MRNA) VACCINE 112
        • 7.4.1.1.2.2 PROTEIN SUBUNIT 112
        • 7.4.1.1.2.3 VIRUS LIKE PARTICLES (VLP) 112
      • 7.4.1.2 BY VARIANT 113
        • 7.4.1.2.1 OMICRON 113
        • 7.4.1.2.2 ALPHA 113
        • 7.4.1.2.3 BETA 113
        • 7.4.1.2.4 DELTA 113
        • 7.4.1.2.5 OTHERS 113
    • 7.4.2 INFLUENZA 114
      • 7.4.2.1 INACTIVATED INFLUENZA VACCINE (IIV) 114
      • 7.4.2.2 RECOMBINANT INFLUENZA VACCINE (RIV) 114
      • 7.4.2.3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) 114
    • 7.4.3 RESPIRATORY SYNCITIAL VIRUS (RSV) 114
    • 7.4.4 OTHERS 114
  • 7.5 MONOCLONAL ANTIBODIES 115
    • 7.5.1 BY TYPE 115
      • 7.5.1.1 BARICITINIB 116
      • 7.5.1.2 REGEN-COV (CASIRIVIMAB AND IMDEVIMAB) 116
      • 7.5.1.3 TOCILIZUMAB 116
      • 7.5.1.4 SARILUMAB 116
      • 7.5.1.5 SOTROVIMAB 116
      • 7.5.1.6 BAMLANIVIMAB AND ETESEVIMAB 116
      • 7.5.1.7 CIGLAVIMAB AND TIXAGEVIMAB (EVUSHELD) 116
      • 7.5.1.8 OTHERS 116
    • 7.5.2 BY DRUG TYPE 117
      • 7.5.2.1 BRANDED 117
      • 7.5.2.2 GENERIC 117
  • 7.6 OTHERS 117

8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE 118

  • 8.1 OVERVIEW 119
  • 8.2 PRESCRIPTION BASED 122
  • 8.3 OTC 122

9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 123

  • 9.1 OVERVIEW 124
  • 9.2 NASAL 127
  • 9.3 ORAL 127
    • 9.3.1 TABLETS 128
    • 9.3.2 LIQUID 128
    • 9.3.3 OTHER 128
  • 9.4 INJECTABLE 128
    • 9.4.1 INTRAVENOUS 129
    • 9.4.2 OTHERS 129

10 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE 130

  • 10.1 OVERVIEW 131
  • 10.2 COVID 134
  • 10.3 RHINOVIRUS (COMMON COLD) 134
  • 10.4 RESPIRATORY SYNCYTIAL VIRUS (RSV) 135
  • 10.5 INFLUENZA (FLU) 135
  • 10.6 PARAINFLUENZA 136
    • 10.6.1 HPIV-1 136
    • 10.6.2 HPIV-2 136
    • 10.6.3 HPIV-3 136
    • 10.6.4 HPIV-4 137
  • 10.7 ADENOVIRUSES 137
  • 10.8 ENTEROVIRUS 137
    • 10.8.1 COXSACKIEVIRUS (CV) 138
    • 10.8.2 POLIOVIRUS (PV) 138
    • 10.8.3 OTHERS 138
  • 10.9 OTHERS 138

11 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE 139

  • 11.1 OVERVIEW 140
  • 11.2 LOWER RESPIRATORY INFECTIONS 143
  • 11.3 UPPER RESPIRATORY INFECTIONS 143 

12 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION 144

  • 12.1 OVERVIEW 145
  • 12.2 GERIATRIC 148
  • 12.3 PEDIATRIC 148
  • 12.4 ADULTS 149

13 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER 150

  • 13.1 OVERVIEW 151
  • 13.2 MALE 154
  • 13.3 FEMALE 154

14 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER 155

  • 14.1 OVERVIEW 156
  • 14.2 HOSPITALS 159
    • 14.2.1 PRIVATE 159
    • 14.2.2 PUBLIC 159
  • 14.3 AMBULATORY SURGICAL CENTERS 160
  • 14.4 CLINICS 160
  • 14.5 HOME CARE SETTINGS 161
  • 14.6 RESEARCH INSTITUTES AND ACADEMIC CENTERS 161

15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 162

  • 15.1 OVERVIEW 163
  • 15.2 DIRECT TENDER 166
  • 15.3 RETAIL SALES 166
    • 15.3.1 HOSPITAL PHARMACIES 167
    • 15.3.2 RETAIL PHARMACIES 167
    • 15.3.3 ONLINE PHARMACIES 167
  • 15.4 OTHERS 167

16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION 168

  • 16.1 OVERVIEW 169
  • 16.2 NORTH AMERICA 173
    • 16.2.1 U.S. 183
    • 16.2.2 CANADA 193
    • 16.2.3 MEXICO 203
  • 16.3 EUROPE 213
    • 16.3.1 GERMANY 224
    • 16.3.2 FRANCE 234
    • 16.3.3 U.K. 244
    • 16.3.4 ITALY 254
    • 16.3.5 RUSSIA 264
    • 16.3.6 SPAIN 274
    • 16.3.7 TURKEY 284
    • 16.3.8 NETHERLANDS 294
    • 16.3.9 SWITZERLAND 304
    • 16.3.10 BELGIUM 314
    • 16.3.11 REST OF EUROPE 324
  • 16.4 ASIA PACIFIC 325
    • 16.4.1 CHINA 336
    • 16.4.2 JAPAN 346
    • 16.4.3 INDIA 356
    • 16.4.4 SOUTH KOREA 366
    • 16.4.5 AUSTRALIA 376
    • 16.4.6 SINGAPORE 386
    • 16.4.7 THAILAND 396
    • 16.4.8 MALAYSIA 406
    • 16.4.9 INDONESIA 416
    • 16.4.10 PHILIPPINES 426
    • 16.4.11 REST OF ASIA-PACIFIC 436
  • 16.5 SOUTH AMERICA 437
    • 16.5.1 BRAZIL 447
    • 16.5.2 ARGENTINA 457
    • 16.5.3 REST OF SOUTH AMERICA 467
  • 16.6 MIDDLE EAST AND AFRICA 468
    • 16.6.1 SOUTH AFRICA 478
    • 16.6.2 SAUDI ARABIA 488
    • 16.6.3 U.A.E. 498
    • 16.6.4 EGYPT 508
    • 16.6.5 ISRAEL 518
    • 16.6.6 REST OF MIDDLE EAST AND AFRICA 528

17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY LANDSCAPE 529

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 529
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 530
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 531
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 532

18 SWOT ANALYSIS 533

19 COMPANY PROFILE 534

  • 19.1 PFIZER INC. 534
    • 19.1.1 COMPANY SNAPSHOT 534
    • 19.1.2 REVENUE ANALYSIS 534
    • 19.1.3 COMPANY SHARE ANALYSIS 535
    • 19.1.4 PRODUCT PORTFOLIO 535
    • 19.1.5 RECENT DEVELOPMENTS 536
  • 19.2 GSK PLC 537
    • 19.2.1 COMPANY SNAPSHOT 537
    • 19.2.2 REVENUE ANALYSIS 537
    • 19.2.3 COMPANY SHARE ANALYSIS 538
    • 19.2.4 PRODUCT PORTFOLIO 538
    • 19.2.5 RECENT DEVELOPMENT 539
  • 19.3 GILEAD SCIENCES, INC 540
    • 19.3.1 COMPANY SNAPSHOT 540
    • 19.3.2 REVENUE ANALYSIS 540
    • 19.3.3 COMPANY SHARE ANALYSIS 541
    • 19.3.4 PRODUCT PORTFOLIO 541
    • 19.3.5 RECENT DEVELOPMENT 541
  • 19.4 F. HOFFMANN-LA ROCHE LTD 542
    • 19.4.1 COMPANY SNAPSHOT 542
    • 19.4.2 REVENUE ANALYSIS 542
    • 19.4.3 COMPANY SHARE ANALYSIS 543
    • 19.4.4 PRODUCT PORTFOLIO 543
    • 19.4.5 RECENT DEVELOPMENTS 545
      • 19.4.5.1 AGREEMENT 545
  • 19.5 JOHNSON & JOHNSON SERVICES, INC. 546
    • 19.5.1 COMPANY SNAPSHOT 546
    • 19.5.2 REVENUE ANALYSIS 546
    • 19.5.3 COMPANY SHARE ANALYSIS 547
    • 19.5.4 PRODUCT PORTFOLIO 547
    • 19.5.5 RECENT DEVELOPMENT 547
  • 19.6 ASTRAZENECA 548
    • 19.6.1 COMPANY SNAPSHOT 548
    • 19.6.2 REVENUE ANALYSIS 548
    • 19.6.3 PRODUCT PORTFOLIO 549
    • 19.6.4 RECENT DEVELOPMENT 549
  • 19.7 BHARAT BIOTECH 550
    • 19.7.1 COMPANY SNAPSHOT 550
    • 19.7.2 PRODUCT PORTFOLIO 550
    • 19.7.3 RECENT DEVELOPMENTS 551
  • 19.8 BIOLOGICAL E LIMITED 552
    • 19.8.1 COMPANY SNAPSHOT 552
    • 19.8.2 PRODUCT PORTFOLIO 552
    • 19.8.3 RECENT DEVELOPMENT 552
  • 19.9 CELLTRION HEALTHCARE CO., LTD. 553
    • 19.9.1 COMPANY SNAPSHOT 553
    • 19.9.2 REVENUE ANALYSIS 553
    • 19.9.3 PRODUCT PORTFOLIO 554
    • 19.9.4 RECENT DEVELOPMENT 554
  • 19.10 INFLARX N.V. 555
    • 19.10.1 COMPANY SNAPSHOT 555
    • 19.10.2 PRODUCT PORTFOLIO 555
    • 19.10.3 RECENT DEVELOPMENT 556
  • 19.11 LILLY 557
    • 19.11.1 COMPANY SNAPSHOT 557
    • 19.11.2 REVENUE ANALYSIS 557
    • 19.11.3 PRODUCT PORTFOLIO 558
    • 19.11.4 RECENT DEVELOPMENT 558
  • 19.12 REGENERON PHARMACEUTICALS INC. 559
    • 19.12.1 COMPANY SNAPSHOT 559
    • 19.12.2 REVENUE ANALYSIS 559
    • 19.12.3 PRODUCT PORTFOLIO 560
    • 19.12.4 RECENT DEVELOPMENT 560
  • 19.13 SERUM INSTITUTE OF INDIA PVT. LTD 561
    • 19.13.1 COMPANY SNAPSHOT 561
    • 19.13.2 PRODUCT PORTFOLIO 561
    • 19.13.3 RECENT DEVELOPMENT 561

 

  • 19.14 SINOVAC 562
    • 19.14.1 COMPANY SNAPSHOT 562
    • 19.14.2 REVENUE ANALYSIS 562
    • 19.14.3 PRODUCT PORTFOLIO 563
    • 19.14.4 RECENT DEVELOPMENT 563
  • 19.15 SWEDISH ORPHAN BIOVITRUM AB (PUBL) 564
    • 19.15.1 COMPANY SNAPSHOT 564
    • 19.15.2 REVENUE ANALYSIS 564
    • 19.15.3 PRODUCT PORTFOLIO 565
    • 19.15.4 RECENT DEVELOPMENT 565

20 QUESTIONNAIRE 566

21 RELATED REPORTS 570

LIST OF TABLES

  • TABLE 1 BRAND REVENUE ANALYSIS FOR VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET 87
  • TABLE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 105
  • TABLE 3 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DTUGS (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 106
  • TABLE 4 GLOBAL NON-STEROIDAL ANTI- INFLAMMATORY DRUGS(NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 106
  • TABLE 5 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 107
  • TABLE 6 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 108
  • TABLE 7 GLOBAL ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 109
  • TABLE 8 GLOBAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 110
  • TABLE 9 GLOBAL VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 110
  • TABLE 10 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 11 GLOBAL WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 12 GLOBAL COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 112
  • TABLE 13 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT, 2022-2031 (USD MILLION) 113
  • TABLE 14 GLOBAL INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 114
  • TABLE 15 GLOBAL MONOCLONAL ANTIIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 115
  • TABLE 16 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 115
  • TABLE 17 GLOBAL MONOCLONAL ANTIBODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 117
  • TABLE 18 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 117
  • TABLE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
  • TABLE 20 GLOBAL PRESCRIPTION BASED IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 122
  • TABLE 21 GLOBAL OTC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 122
  • TABLE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 126
  • TABLE 23 GLOBAL NASAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 127
  • TABLE 24 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 127
  • TABLE 25 GLOBAL ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 128
  • TABLE 26 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 128
  • TABLE 27 GLOBAL INJECTABLE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 129
  • TABLE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 29 GLOBAL COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 134
  • TABLE 30 GLOBAL RHINOVIRUS (COMMON COLD) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 134
  • TABLE 31 GLOBAL RESPIRATORY SYNCYTIAL VIRUS (RSV) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 135
  • TABLE 32 GLOBAL INFLUENZA (FLU) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 135
  • TABLE 33 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 136
  • TABLE 34 GLOBAL PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 136
  • TABLE 35 GLOBAL ADENOVIRUSES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 137
  • TABLE 36 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 137
  • TABLE 37 GLOBAL ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 38 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 138
  • TABLE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 40 GLOBAL LOWER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 143
  • TABLE 41 GLOBAL UPPER RESPIRATORY INFECTIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 143
  • TABLE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 147
  • TABLE 43 GLOBAL GERIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 148
  • TABLE 44 GLOBAL PEDIATRIC IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 148
  • TABLE 45 GLOBAL ADULTS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 149
  • TABLE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 153
  • TABLE 47 GLOBAL MALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 154
  • TABLE 48 GLOBAL FEMALE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 154
  • TABLE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 158
  • TABLE 50 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 159
  • TABLE 51 GLOBAL HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 52 GLOBAL AMBULATORY SURGICAL CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 160
  • TABLE 53 GLOBAL CLINICS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 160
  • TABLE 54 GLOBAL HOME CARE SETTINGS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 161
  • TABLE 55 GLOBAL RESEARCH INSTITUTES AND ACADEMIC CENTERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 161
  • TABLE 56 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 165
  • TABLE 57 GLOBAL DIRECT TENDER IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 166
  • TABLE 58 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 166
  • TABLE 59 GLOBAL RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 60 GLOBAL OTHERS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 167
  • TABLE 61 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION) 172
  • TABLE 62 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 173
  • TABLE 63 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 64 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 65 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 66 NORTH AMERICA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 67 NORTH AMERICA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 175
  • TABLE 68 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 175
  • TABLE 69 NORTH AMERICA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 176
  • TABLE 70 NORTH AMERICA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 176
  • TABLE 71 NORTH AMERICA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 176
  • TABLE 72 NORTH AMERICA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 177
  • TABLE 73 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 74 NORTH AMERICA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 75 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 76 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 178
  • TABLE 77 NORTH AMERICA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 179
  • TABLE 78 NORTH AMERICA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 179
  • TABLE 79 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 179
  • TABLE 80 NORTH AMERICA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 81 NORTH AMERICA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 82 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 83 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 181
  • TABLE 84 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 181
  • TABLE 85 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 181
  • TABLE 86 NORTH AMERICA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 182
  • TABLE 87 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 182
  • TABLE 88 NORTH AMERICA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 182
  • TABLE 89 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 90 U.S. NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 91 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 92 U.S. ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 93 U.S. VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 185
  • TABLE 94 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 185
  • TABLE 95 U.S. WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 185
  • TABLE 96 U.S. COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 186
  • TABLE 97 U.S. COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 186
  • TABLE 98 U.S. INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 186
  • TABLE 99 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 100 U.S. MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 101 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 102 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 188
  • TABLE 103 U.S. ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 188
  • TABLE 104 U.S. INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 189
  • TABLE 105 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 189
  • TABLE 106 U.S. PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 190
  • TABLE 107 U.S. ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 190
  • TABLE 108 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 190
  • TABLE 109 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 191
  • TABLE 110 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 191
  • TABLE 111 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 191
  • TABLE 112 U.S. HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 192
  • TABLE 113 U.S. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 192
  • TABLE 114 U.S. RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 192
  • TABLE 115 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 116 CANADA NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 117 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 118 CANADA ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 119 CANADA VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 195
  • TABLE 120 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 195
  • TABLE 121 CANADA WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 195
  • TABLE 122 CANADA COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 196
  • TABLE 123 CANADA COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 196
  • TABLE 124 CANADA INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 196
  • TABLE 125 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 126 CANADA MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 127 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 128 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 198
  • TABLE 129 CANADA ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 198
  • TABLE 130 CANADA INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 198
  • TABLE 131 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 132 CANADA PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 133 CANADA ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 200
  • TABLE 134 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 200
  • TABLE 135 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 200
  • TABLE 136 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 201
  • TABLE 137 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 201
  • TABLE 138 CANADA HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 201
  • TABLE 139 CANADA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 202
  • TABLE 140 CANADA RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 202
  • TABLE 141 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 142 MEXICO NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 143 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 144 MEXICO ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 145 MEXICO VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 205
  • TABLE 146 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 205
  • TABLE 147 MEXICO WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 205
  • TABLE 148 MEXICO COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 206
  • TABLE 149 MEXICO COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 206
  • TABLE 150 MEXICO INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 206
  • TABLE 151 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 152 MEXICO MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 153 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 154 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 208
  • TABLE 155 MEXICO ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 208
  • TABLE 156 MEXICO INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 209
  • TABLE 157 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 209
  • TABLE 158 MEXICO PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 159 MEXICO ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 160 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 161 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 211
  • TABLE 162 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 211
  • TABLE 163 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 211
  • TABLE 164 MEXICO HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 212
  • TABLE 165 MEXICO VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 212
  • TABLE 166 MEXICO RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 212
  • TABLE 167 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 213
  • TABLE 168 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 214
  • TABLE 169 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
  • TABLE 170 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
  • TABLE 171 EUROPE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 215
  • TABLE 172 EUROPE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 216
  • TABLE 173 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 216
  • TABLE 174 EUROPE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 216
  • TABLE 175 EUROPE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 217
  • TABLE 176 EUROPE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 217
  • TABLE 177 EUROPE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 217
  • TABLE 178 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 179 EUROPE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 180 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 219
  • TABLE 181 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 219
  • TABLE 182 EUROPE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 219
  • TABLE 183 EUROPE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 220
  • TABLE 184 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 220
  • TABLE 185 EUROPE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 221
  • TABLE 186 EUROPE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 221
  • TABLE 187 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 221
  • TABLE 188 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 222
  • TABLE 189 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 222
  • TABLE 190 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 222
  • TABLE 191 EUROPE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 223
  • TABLE 192 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 223
  • TABLE 193 EUROPE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 223
  • TABLE 194 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 224
  • TABLE 195 GERMANY NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
  • TABLE 196 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 225
  • TABLE 197 GERMANY ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 225
  • TABLE 198 GERMANY VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 226
  • TABLE 199 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 226
  • TABLE 200 GERMANY WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 226
  • TABLE 201 GERMANY COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 227
  • TABLE 202 GERMANY COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 227
  • TABLE 203 GERMANY INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 227
  • TABLE 204 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 228
  • TABLE 205 GERMANY MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 228
  • TABLE 206 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 229
  • TABLE 207 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 229
  • TABLE 208 GERMANY ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 229
  • TABLE 209 GERMANY INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 230
  • TABLE 210 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 230
  • TABLE 211 GERMANY PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 231
  • TABLE 212 GERMANY ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 231
  • TABLE 213 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 231
  • TABLE 214 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 232
  • TABLE 215 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 232
  • TABLE 216 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 232
  • TABLE 217 GERMANY HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 233
  • TABLE 218 GERMANY VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 233
  • TABLE 219 GERMANY RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 233
  • TABLE 220 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 234
  • TABLE 221 FRANCE NON-STEROIDAL ANTI-INFLAMMATORY (NSAIDS) IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 234
  • TABLE 222 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 235
  • TABLE 223 FRANCE ANTIVIRAL MEDICATIONS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 235
  • TABLE 224 FRANCE VACCINES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE , 2022-2031 (USD MILLION) 236
  • TABLE 225 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 236
  • TABLE 226 FRANCE WHOLE VIRUS VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 236
  • TABLE 227 FRANCE COMPONENT VIRAL VACCINE IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 237
  • TABLE 228 FRANCE COVID IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY VARIANT , 2022-2031 (USD MILLION) 237
  • TABLE 229 FRANCE INFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE , 2022-2031 (USD MILLION) 237
  • TABLE 230 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
  • TABLE 231 FRANCE MONOCLONAL ANTIBDODIES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 238
  • TABLE 232 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
  • TABLE 233 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 239
  • TABLE 234 FRANCE ORAL IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 239
  • TABLE 235 FRANCE INJECTABLES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 239
  • TABLE 236 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 240
  • TABLE 237 FRANCE PARAINFLUENZA IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 240
  • TABLE 238 FRANCE ENTEROVIRUS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISEASE TYPE, 2022-2031 (USD MILLION) 241
  • TABLE 239 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION TYPE, 2022-2031 (USD MILLION) 241
  • TABLE 240 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY POPULATION, 2022-2031 (USD MILLION) 241
  • TABLE 241 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION) 242
  • TABLE 242 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 242
  • TABLE 243 FRANCE HOSPITALS IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION) 242
  • TABLE 244 FRANCE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 243
  • TABLE 245 FRANCE RETAIL SALES IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 243
  • TABLE 246 U.K. VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY TREATMENT TYPE, 2022-2031 (USD MILLION) 244

LIST OF FIGURES

  • FIGURE 1 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION 68
  • FIGURE 2 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DATA TRIANGULATION 71
  • FIGURE 3 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DROC ANALYSIS 72
  • FIGURE 4 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 73
  • FIGURE 5 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 73
  • FIGURE 6 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 74
  • FIGURE 7 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: DBMR MARKET POSITION GRID 75
  • FIGURE 8 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: MARKET END USER COVERAGE GRID 77
  • FIGURE 9 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SEGMENTATION 81
  • FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET AND GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031 82
  • FIGURE 11 THE INCREASING PREVALENCE OF VIRAL RESPIRATORY DISEASES IS DRIVING THE GROWTH OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 83
  • FIGURE 12 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET IN 2024 AND 2031 83
  • FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031 84
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET 92
  • FIGURE 15 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2023 103
  • FIGURE 16 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, 2024-2031 (USD MILLION) 104
  • FIGURE 17 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2024-2031) 104
  • FIGURE 18 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 105
  • FIGURE 19 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2023 119
  • FIGURE 20 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION) 120
  • FIGURE 21 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, CAGR (2024-2031) 120
  • FIGURE 22 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY TYPE, LIFELINE CURVE 121
  • FIGURE 23 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023 124
  • FIGURE 24 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION) 125
  • FIGURE 25 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031) 125
  • FIGURE 26 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 126
  • FIGURE 27 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2023 131
  • FIGURE 28 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, 2024-2031 (USD MILLION) 132
  • FIGURE 29 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2024-2031) 132
  • FIGURE 30 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE 133
  • FIGURE 31 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2023 140
  • FIGURE 32 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, 2024-2031 (USD MILLION) 141
  • FIGURE 33 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, CAGR (2024-2031) 141
  • FIGURE 34 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY INFECTION TYPE, LIFELINE CURVE 142
  • FIGURE 35 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2023 145
  • FIGURE 36 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, 2024-2031 (USD MILLION) 146
  • FIGURE 37 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, CAGR (2024-2031) 146
  • FIGURE 38 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY POPULATION, LIFELINE CURVE 147
  • FIGURE 39 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2023 151
  • FIGURE 40 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION) 152
  • FIGURE 41 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, CAGR (2024-2031) 152
  • FIGURE 42 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY GENDER, LIFELINE CURVE 153
  • FIGURE 43 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2023 156
  • FIGURE 44 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION) 157
  • FIGURE 45 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, CAGR (2024-2031) 157
  • FIGURE 46 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY END USER, LIFELINE CURVE 158
  • FIGURE 47 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023 163
  • FIGURE 48 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 164
  • FIGURE 49 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 164
  • FIGURE 50 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 165
  • FIGURE 51 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: SNAPSHOT (2023) 170
  • FIGURE 52 GLOBAL VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%) 529
  • FIGURE 53 NORTH AMERICA VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%) 530
  • FIGURE 54 EUROPE VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%) 531
  • FIGURE 55 AISA-PACIFIC VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET: COMPANY SHARE 2023 (%) 532